Regulus Therapeutics, the microRNA drugs joint venture of Alnylam Pharmaceuticals and Isis Pharmaceuticals, has named Hubert Chen as its vice president of translational medicine.
In the role, Chen will be "responsible for leading the translation of the important biological discoveries in the field of microRNA therapeutics into new medicines," Regulus said.
Before joining Regulus, Chen was senior director of clinical research at Amylin Pharmaceuticals. Before that, he was associate director of medical sciences at Amgen.
He holds an MD from Columbia University and a BAS in political sciences and biological sciences from Stanford University.